Use search to browse all 100+ peptides
AM-833, Long-acting amylin analogue
A long-acting amylin receptor agonist used for obesity and type 2 diabetes treatment by enhancing satiety, reducing food intake, and aiding weight loss.
Garvey. W Timothy WT; Blüher. Matthias M; Osorto Contreras. Cynthia Karenina CK; Davies. Melani...
A new drug combo called CagriSema (cagrilintide + semaglutide, each 2.4 mg) made people with obesity lose about 20% of their body weight over 68 weeks, far more than placebo and similar to the best weight‑loss drugs we know. The side‑effects were mostly mild stomach upset that went away on its own.
D'Ascanio. Antonella M AM; Mullally. Jamie A JA; Frishman. William H WH
Cagrilintide is a new, long‑acting drug that mimics the hormone amylin, which helps you feel full. When used alone or together with the GLP‑1 drug semaglutide, it cuts appetite more than either drug by itself, leading to notable weight loss in early trials. This suggests that combining two different appetite‑control pathways could be a powerful strategy for people looking to lose weight and improve metabolic health.
Dutta. Deep D; Nagendra. Lakshmi L; Harish. B G BG; Sharma. Meha M; Joshi. Ameya A; Hathur. Basavana...
A new analysis of three clinical trials shows that the drug combo called Cagrisema (cagrilintide + semaglutide) can cut body weight by about 9% (roughly 9 kg) in 20‑32 weeks—much more than semaglutide alone. Using cagrilintide by itself gives about the same weight loss as semaglutide or liraglutide, but with noticeably less vomiting. Overall safety looks similar, though the combo causes more stomach upset.
Frias. Juan P JP; Deenadayalan. Srikanth S; Erichsen. Lars L; Knop. Filip K FK; Lingvay. Ildiko I; M...
In a 32‑week trial with 92 adults who have type 2 diabetes, a once‑weekly combo of semaglutide (2.4 mg) and cagrilintide (2.4 mg) lowered blood sugar about as well as semaglutide alone but caused dramatically more weight loss – roughly 15% of body weight versus 5% with semaglutide and 8% with cagrilintide. Side effects were mostly mild stomach issues and no severe low‑blood‑sugar events were seen.
Enebo. Lone B LB; Berthelsen. Kasper K KK; Kankam. Martin M; Lund. Michael T MT; Rubino. Domenica M...
A small early‑stage trial tested weekly injections of the amylin‑like peptide cagrilintide together with the GLP‑1 drug semaglutide (2.4 mg) in healthy adults with obesity. The combo was safe, causing mostly mild gastrointestinal issues, and showed a clear extra weight‑loss benefit – about 15‑17% loss of body weight versus roughly 9% with semaglutide alone. Blood levels of each drug didn’t interfere with each other, and the drugs behaved as expected in the body.
Lau. David C W DCW; Erichsen. Lars L; Francisco. Ann Marie AM; Satylganova. Altynai A; le Roux. Care...
In a 26‑week trial, weekly injections of the amylin‑like peptide cagrilintide caused dose‑dependent weight loss of about 6% to almost 11% in adults with overweight or obesity, outperforming placebo and slightly beating daily liraglutide. The drug was generally well tolerated, with the most common side effects being nausea, constipation or diarrhea and mild injection‑site reactions.
Kruse. Thomas T; Hansen. Jakob Lerche JL; Dahl. Kirsten K; Schäffer. Lauge L; Sensfuss. Ulrich...
Cagrilintide is a new, stable version of the hormone amylin that lasts a long time in the body, so it can be given less often than older drugs. Early trials show it helps people lose a lot of weight, either by itself or when combined with the popular GLP‑1 drug semaglutide.
Yao. Haiqiang H; Zhang. Anqi A; Li. Delong D; Wu. Yuqi Y; Wang. Chong-Zhi CZ; Wan. Jin-Yi JY; Yuan....
A big review of many diabetes drugs shows that the combo of semaglutide plus cagrilintide (called CagriSema) cuts weight the most—about 14 kg on average—while also improving blood sugar. It works better than other GLP‑1 drugs, but high doses can cause stomach upset.
Gogineni. Prathima P; Melson. Eka E; Papamargaritis. Dimitris D; Davies. Melanie M
New oral GLP‑1 pills (like oral semaglutide and the experimental orforglipron) and combo drugs that hit several gut hormones (such as tirzepatide and the cagrilintide + semaglutide mix) are now in late‑stage trials. They can lower blood sugar, cut weight by 15% or more, and may bring heart‑kidney benefits, all without the need for daily injections.
Bailey. Clifford J CJ; Flatt. Peter R PR; Conlon. J Michael JM
The study looks …
Sidrak. Wael R WR; Kalra. Sanjay S; Kalhan. Atul A
The review says that cagrilintide, an amylin receptor agonist, can cause big weight loss on its own or when paired with the GLP‑1 drug semaglutide. It’s not yet approved for weight loss, but early trials show it works well and could become a new tool for people trying to lose fat and improve metabolism.
Panou. Theodoros T; Gouveri. Evanthia E; Popovic. Djordje S DS; Papanas. Nikolaos N
Amylin is a hormone that tells you when you’re full. Two synthetic versions—pramlintide and the newer cagrilintide—have been tested in people without diabetes to see if they can help lose weight. Pramlintide gives a modest 3%+ drop in body weight with few side effects, while cagrilintide has already shown more than 10% weight loss in early trials, though it can cause nausea. Researchers think mixing amylin drugs with other weight‑loss agents could make the effect even bigger.
Son. Jang Won JW; le Roux. Carel W CW; Blüher. Matthias M; Nauck. Michael A MA; Lim. Soo S
New drugs that hit several gut hormone receptors at once—like GLP‑1, GIP, glucagon, and amylin—are showing bigger drops in weight and better blood‑sugar control than single‑target drugs. One combo, CagriSema (cagrilintide plus semaglutide), especially boosts fullness and glucose handling. Oral pills that act like GLP‑1 are also on the horizon, making treatment easier.
Jacobsen. Julie Mie JM; Halling. Jens Frey JF; Blom. Ida I; Moreno Martinez. Jaime J; Hald. Bjø...
The study …
Sun. Xiao X; Yang. Dawei D; Li. Yan Y; Shi. Jingjing J; Zhang. Xiaolong X; Yi. Tingzhuang T
A new frog‑derived GLP‑1 peptide (bGLP‑10) works much better than the popular drug semaglutide at lowering blood sugar and appetite in obese mice. When bGLP‑10 is paired with the amylin drug cagrilintide, the mice lose a huge amount of weight (about 38% of their body weight), far more than any other single drug or the semaglutide‑cagrilintide combo.
Al-Harbi. Faisal A FA; Alsaif. Ahmed K AK; Almutairi. Atheer G AG; Alshehri. Hussam J HJ; Aleidan. E...
A big data analysis of seven obesity/diabetes trials shows that the amylin‑pathway drug cagrilintide (CagriSema) works better than similar peptides and points to a sweet‑spot dose of about 10–20 mg injected under the skin. Weight loss keeps improving for up to a year, while blood‑sugar benefits show up in 6‑8 months. Side‑effects in the gut are manageable if you stay in that dose range, and most people stay on the drug.
Briere. Daniel A DA; Qu. Hongchang H; Lansu. Katherine K; He. Minxia Michelle MM; Moyers. Julie S JS...
Eloralintide is a new peptide that mainly hits the AMY1R receptor, causing less nausea than older drugs like cagrilintide. In obese rats it cut food intake and dropped body weight (mostly fat) in a dose‑dependent way. In a small human safety study, a single weekly dose of 4 mg cut weight by about 2.5% after four weeks and 12 mg cut it by about 4%, with only mild stomach side effects, suggesting it could be taken once a week for weight control.
Verma. Subodh S; Böttcher. Morten M; Brown. Paul P; Dicker. Dror D; Rubino. Domenica D; Sbracci...
In a 68‑week study of people with overweight or obesity (but no diabetes), a weekly injection that mixes two peptides—semaglutide and cagrilintide (called CagriSema)—cut systolic blood pressure by about 11 mm Hg and diastolic pressure by about 5 mm Hg, far more than a placebo. About two‑thirds of participants on CagriSema hit the blood‑pressure goals, versus one‑third on placebo, and many were able to cut back or stop their other blood‑pressure medicines.
Li. Chengwen C; Lin. Chu C; Cai. Xiaoling X; Lv. Fang F; Yang. Wenjia W; Ji. Linong L
A big review of weight‑loss drugs found that, overall, they don’t change the chance of getting cancers linked to obesity. However, a special group of drugs called co‑agonists – which includes the peptide cagrilintide – cut the overall risk of those cancers by about half, and each 5 kg of weight loss they cause may lower cancer risk by roughly 20%.
Gabe. Maria B N MBN; Fuhr. Rainard R; Sinn. Angela A; Eliasen. Astrid A; Berthelsen. Kasper K KK; Ku...
A clinical trial in healthy volunteers showed that taking the weekly injection of cagrilintide up to 4.5 mg does not meaningfully stretch the heart's QT interval, meaning it likely won’t raise the risk of dangerous heart rhythm problems.